CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Gillison, ML
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Licitra, L
Harrington, KJ
Kasper, S
Vokes, EE
Even, C
Worden, F
Saba, NF
Iglesias Docampo, LC
Haddad, R
Rordorf, T
Kiyota, N
Tahara, M
Monga, M
Lynch, M
Li, L
Ferris, RL
Blumenschein, G
Fayette, J
Guigay, J
Colevas, AD
Licitra, L
Harrington, KJ
Kasper, S
Vokes, EE
Even, C
Worden, F
Saba, NF
Iglesias Docampo, LC
Haddad, R
Rordorf, T
Kiyota, N
Tahara, M
Monga, M
Lynch, M
Li, L
Ferris, RL
Document Type
Journal Article
Date
2018-09-01
Date Accepted
2018-03-06
Abstract
Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
Citation
The oncologist, 2018, 23 (9), pp. 1079 - 1082
Source Title
Publisher
WILEY
ISSN
1083-7159
eISSN
1549-490X
Research Team
Targeted Therapy